signs of abnormal energy metabolism (elevated body flu~d lactate and consistent abnormal unne organic acid%), and 3) the lack of another diagnosis after a complete work-up. In our expenence at Childrens Hospital Los Angeles. children fulfilling the above crileria almost always have abnormal muscle biopsies, usually mitochondnal proliferation and lipid storage. Although only a small m~nority of these ch~ldren have a definable abnormality on the genetic or protein level, In thc majonty the clinical manifestations arc s~milar enough lo be cons~dered syndromic, suggesting a single pathophysiological mechanism. In our clinical expenence. ant~cipatory guldance regarding potential future compl~cations has a pos~tive role In the care of these childm.. Many of the common compl~cations are debilitating and d~fticult to d~agnosis, but are readily amenable to specific treaunenu once recogn~zed by the parent or yhyslclan.
Although migraine headaches are well described as pan of mitochondnal diseze. the scope and range of lransient "migra~ne-like" neurological dysfuncl~on is generally unappreciated. In addition to headaches, other symptoms such as abdomll~al pain. cycllc vomiting. muscle cramps, and neurovascular dysbophy are common. nese symp!oms can be severe and debilitating, and often occur in the same subset of ptients who may present with one or any number of the abovc symptoms. In most cases, .hes? manifestations are found In children wlth normal or near-normal intelligence and with matrilineal inheritance panems. In each of 15 cases braled (non-blinded) to date, these manifestations resolved upon lreatment with one of the "anti-migraine" agents amitriptyline. cyproheptad~ne or propranolol. The use of caffeine is often helpful ~f given at the onset of symptoms. Gastrointest~nal dysmotll~ty is found In over half of ch~ldren with clinical mitochondrial disease, and often rrsponds to symptomatic therapy. Pancmtitis. absence mzures, hypothyroidism, growth hormone deficiency, renal tubular acidosis, and hearing loss arc addt~onal treatable, yet often cryptic. compl~cations. A case of mitochondrial DNA deletion resulting in multisystem dysfunction is discussed to bring out the well-known uncertainties inherent in the biology of these disorders. The presentation, reminiscent of Rothmund-Thomson Syndrome, as well as subsequent progression of the disease process has been anything but typical, if there is such an entity in mitochondrial disease. The limitation of syndrome nosology based on phenotypic hooks is considered, along with the progressive recognition of the unruly nature of biologic phenomena underlying disease, defeating our attempts to impose order by creating neat pigeon-holes based on perceived morphologic patterns with little or no knowledge of basic biology. While this conundrum can be seen with most genetic d~sorders, to one degree or another, the case of mitochondrial diseases offers the unique perspective that allows us to understand the limits of precision in prognostication, and indeed even in disease definition. Effect~ve pharmacolog~c therap~es of mltochondrlal disease have been llmlted because of our rudlmentarj, albe~t rap~dly expand~ng. knowledge of the many roles m~tochondrla play In the metabol~sm of d~fferentlated, non-growlng cells B~ochem~cal tests of growlng cells In culture do not pred~ct the symptoms observed cl~n~cally In pat~enls w~t h m~tochondr~al d~sease M~tochondr~al funct~on IS not llm~ted to energy product~on Mltochondrla are requlred for the synthesrs of hundreds of chemicals lhat are absolutely requ~red for the normal funct~on of all organ systems State-of-the-art therapy for m~tochondr~al dlsease In chlldren starts w~th a comprehens~ve metabol~c and nutr~t~onal evaluat~on, and the deslgn of a d~e t ta~lored lo the ~n d~v~d u a l needs of the ch~ld The d~et IS deslgned to mlnlmlze lactate and other organlc a c~d product~on and to optlm~ze growth In both chlldren and adults balanced supplements of m~lochondr~al cofactors (CoQ10. B-vltam~ns, folate and b~ot~n) are rout~nely prov~ded, although rlgorous ev~dence for slgnlficant efficacy has been d~fficult to establ~sh Chron~c anlloxldant therapy IS l~kewlse controvers~al In congen~tal m~tochondr~al d~sease, because these pat~ents already have an excess of lntracellular reduc~ng potentlal Carn~t~ne IS used when a documented defic~ency IS establ~shed D~chloroacetate (DCA) IS sometimes used to lower blood and cerebrosp~nal fluld lactates However. In our serles of 50 patlents wlth congen~tal l a c k ac~dem~a, only about 25% of patlents show clear-cut cllnlcal benef~t Some pat~ents appear to deterlorate when lactate IS reduced and make recoveries when the lactate IS perm~tted to rlse to moderate levels In add~tlon. about 5% of patlents have a paradox~cal response In whlch lactate levels rase In response to DCA An emerglng modal~ly of treatment 1s pyr~m~d~ne therapy Tr~acetylur~d~ne (PN401) IS a prodrug of u r~d~n e that IS rap~dly absorbed and converted to ur~dlne Normal ox~dat~ve phosphorylatlon IS requlred for de novo u r~d~n e synthes~s A pilot study of pH401 treatment of mltochondrlal d~sease has demonstrated cl~n~cal beneflt In up to 50% of the pat~ents and has led to Improvement or correct~on of renal tubular acldos~s In 4 of 4 patlents studled wlth mltochondrlal RTAs Also presented is a parent's perspect~ve of the search for clear answers and the personal conclusion this family came to, that uncertainty should be taken as reason for hope.
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